Hoertkorn Richard Charles’s Esperion Therapeutics ESPR Stock Holding History

Hoertkorn Richard Charles’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.32K	Hold	2,000	–	–	﹤0.01%	57
2026 Q1	$5.48K	Hold	2,000	–	–	﹤0.01%	63
2025 Q4	$7.4K	Hold	2,000	–	–	﹤0.01%	67
2025 Q3	$5.3K	Hold	2,000	–	–	﹤0.01%	69
2025 Q2	$1.97K	Hold	2,000	–	–	﹤0.01%	72
2025 Q1	$2.88K	Hold	2,000	–	–	﹤0.01%	73
2024 Q4	$4.4K	Hold	2,000	–	–	﹤0.01%	72
2024 Q3	$3.3K	Hold	2,000	–	–	﹤0.01%	72
2024 Q2	$4.44K	Buy	+2,000	New	+$4.71K	﹤0.01%	72

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Hoertkorn Richard Charles's ESPR Position: Q2 2026 in Review

Hoertkorn Richard Charles held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 2,000 shares worth $6.32K. The position accounts for ﹤0.01% of the portfolio, ranked #57.

Hoertkorn Richard Charles first reported a position in ESPR in Q2 2024 and has held it in 9 quarters since. The position peaked at $7.4K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Hoertkorn Richard Charles held 2,000 shares of Esperion Therapeutics worth $6.32K as of Q2 2026.
Hoertkorn Richard Charles left its Esperion Therapeutics share count unchanged in Q2 2026.
Esperion Therapeutics made up ﹤0.01% of Hoertkorn Richard Charles's portfolio in Q2 2026, its #57 holding.
Hoertkorn Richard Charles first reported a position in Esperion Therapeutics in Q2 2024 and has held it in 9 quarters since.
Hoertkorn Richard Charles's Esperion Therapeutics position peaked at $7.4K in Q4 2025.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Hoertkorn Richard Charles's 13F filing for Q2 2026, filed 23 Jul 2026.